1. Kleihues P, Cavenee WK. Pathology and Genetics of Tumors of the Central Nervous System: World Health Organization Classification of Tumors. Lyons, France: IARC Press; 2000.
2.
2. DeAngelis LM. Brain tumors. N Engl J Med. 2001;344(2):114-123.
3.
3. Watanabe K, Tachibana O, Sato K, et al. Overexpression of EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. 1996;6:217-223.
4.
4. Kleihues P, Ohgaki H. Primary and secondary glioblastomas: from concept to concept to clinical diagnosis. J Neurooncol. 1999;1:44-51.
5.
5. De Santis A, Villani R, Sinisi M, Stocchetti N, Perucca E. Addon phenytoin fails to prevent early seizures after surgery for supratentorial brain tumors: a randomized controlled study. Epilepsia. 2002;43(2):175-182.
6.
6. Hess KR. Extent of resection as a prognostic variable in the treatment of gliomas. J Neurooncol. 1999;42:227-231.
7.
7. Simpson JR, Horton J, Scott C, et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive RTOG clinical trials. Int J Radiat Oncol Biol Phys. 1993;26:239-244.
8.
8. Fine HA, Dear KB, Loeffler JS, Black PM, Conellos GP. Metaanalysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer. 1993;71:2585-2597.
9.
9. Yung WK, Prados MD, Yay-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol. 1999;17:2762-2771.
10.
10. Stupp R, Dietrich PY, Ostermann Kraljevic S, et al. Promising survival for patients with newly diagnonsed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol. 2002;20(5):1375-1382.
11.
11. Prados MD, Scott C, Curran WJ, et al. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: a retrospective review of RTOG protocols comparing survival with carmustine or PCV adjuvant chemotherapy. J Clin Oncol. 1999;17:3389-3395.
12.
12. Stupp R, Regg C. New drugs and combinations for malignant glioma. Forum (Genova).2003;13(1):61-75.
13.
13. Fine HA, Figg WD, Jaeckle K, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol. 2000;18:708-715.
14.
14. Pueschel JK, Ashby LS, Shapiro WR. Brain tumors. In: Cancer Chemotherapy and Biological Response Modifiers, Annual 21. New York, NY: Elsevier; 2003.
15.
15. Inskip PD, Tarone RE, Hatch EE, et al. Cellular-telephone use and brain tumors. N Engl J Med. 2001;344(2):79-86.
16.
16. Kaplan S, Novikov I, Modan B. Nutritional factors in the etiology of brain tumors: potential role of nitrosamines, fat, and cholesterol. Am J Epidemiol. 1997;146:832-841.
17.
17. Salvatore JR, Weitberg AB, Mehta S. Nonionizing electromagnetic fields and cancer: a review. Oncology. 1996;10:563-574.
